Filing identity and reporting period
Important discrepancy: The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2015, filed September 1, 2015. It does not match the request metadata naming Lite Strategy, Inc. and “2013 Q4.” The filing identifies MEI Pharma (NASDAQ: MEIP), an oncology drug-development company.
Business context and key financial metrics
MEI Pharma develops cancer drug candidates and had no operating revenue or marketed products. Its candidates were Pracinostat (Phase II), ME-344 (Phase I/Phase Ib), and PWT143 (first-in-human study initiated in June 2015).
| Metric | FY ended June 30, 2015 | Prior comparable period |
|---|---|---|
| Operating revenue | None reported | None reported |
| Research and development expense | $23.8 million | $19.3 million in FY2014 |
| General and administrative expense | $8.9 million | $7.9 million in FY2014 |
| Total operating expenses / operating loss | $32.8 million | $27.2 million in FY2014 |
| Net loss | $32.7 million; $1.16 per share | $27.1 million; $1.35 per share in FY2014 |
| Net cash used in operations | $28.1 million | $19.5 million in FY2014 |
| Cash, cash equivalents and short-term investments | $63.8 million | $48.8 million at June 30, 2014 |
| Total liabilities | $5.0 million, all current | $4.6 million at June 30, 2014 |
Margins are not meaningful because the company reported no operating revenue. The balance sheet reports no interest-bearing debt; liabilities consisted of accounts payable and accrued liabilities. The unaudited quarter ended June 30, 2015 had a net loss of $5.7 million and basic and diluted loss per share of $0.17.
Changes versus prior periods
- Net loss increased by $5.5 million from FY2014, primarily alongside higher development and administrative spending. R&D expense rose $4.5 million, largely due to Pracinostat Phase II trials and costs for ME-344 and PWT143.
- Operating cash use increased $8.6 million year over year. The December 2014 stock offering provided $43.1 million in net proceeds, and year-end cash and investments increased by $15.0 million.
- Common shares outstanding rose from 21.6 million at June 30, 2014 to 34.2 million at June 30, 2015, reflecting the 11.5 million-share offering and warrant exercises.
Outlook, developments and risks
- Management said existing cash and investments were expected to fund operations for at least the next 12 months. It also anticipated pursuing future financing or strategic partnerships to continue development and expected FY2016 R&D expense to decrease due to clinical-trial timing.
- In a randomized Phase II MDS study of Pracinostat plus azacitidine, the combination did not improve the primary endpoint of overall complete-remission rate versus azacitidine alone. Survival and other event-driven endpoints remained immature; fatigue, gastrointestinal effects and myelosuppression were more frequent with combination treatment and led to more discontinuations.
- In an open-label elderly AML study, interim results showed CR, CRi or MLFS in 27 of 50 patients; median overall survival had not been reached, and the reported one-year survival estimate was approximately 60%. These results were interim and follow-up continued.
- ME-344’s Phase Ib combination study enrolled 13 small-cell lung cancer and 28 ovarian cancer patients; response and survival follow-up was ongoing. PWT143 was expected to enter a patient Phase I study in hematologic cancers in the first half of calendar 2016.
- The business is pre-revenue and expects continuing operating losses and negative operating cash flow. Key risks include clinical-trial failure or delays, regulatory uncertainty, reliance on third-party manufacturers and trial operators, competition, patent challenges, and the need for additional capital and potential shareholder dilution.
- The S*Bio asset agreement includes potential milestone and earnout payments of up to $75.2 million, contingent on specified clinical, regulatory and sales events. The first stated milestone is due upon first dosing in a Phase III or other pivotal trial.
Most important facts to verify
- Confirm the issuer and period: the source is MEI Pharma’s FY2015 10-K, not a Lite Strategy 2013 Q4 filing.
- Review updated Pracinostat trial data, particularly survival outcomes in AML and the immature endpoints and tolerability findings in MDS.
- Assess cash runway against actual operating cash use, clinical-trial plans and expected financing needs.
- Check dilution exposure from outstanding options, warrants, future equity offerings and the S*Bio contingent-payment terms.
- Review the full audited financial statements and risk disclosures. The auditor gave an unqualified opinion, and management and the auditor reported effective internal control over financial reporting as of June 30, 2015.